Synopsis
Synopsis
0
EU WC
0
KDMF
0
NDC API
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Feostat
2. Ferrocap
3. Fersaday
4. Fersamal
5. Ferval
6. Fumar
7. Galfer
8. Ircon
9. Nephro-fer
10. Palafer
11. Rulofer N
1. Iron(ii) Fumarate
2. 141-01-5
3. Feostat
4. Palafer
5. Galfer
6. Ircon
7. Ercoferro
8. Ferrofume
9. Tolferain
10. Cpiron
11. Hemoton
12. Toleron
13. Tolifer
14. Erco-fer
15. Ferrousfumarate
16. Iron(2+) Fumarate
17. Iron Fumarate
18. 2-butenedioic Acid (2e)-, Iron(2+) Salt (1:1)
19. Fumaric Acid, Iron(2+) Salt (1:1)
20. 2-butenedioic Acid (e)-, Iron(2+) Salt (1:1)
21. R5l488ry0q
22. 2-butenedioic Acid, (e)-, Iron(2+) Salt
23. Fersamal
24. Fumar
25. (e)-but-2-enedioate;iron(2+)
26. Feroton
27. Ferronat
28. Ferrone
29. Ferrotemp
30. Fumafer
31. Fumiron
32. Firon
33. One-iron
34. Fumar-f
35. Ferrocite
36. Fumaric Acid, Iron(2+) Salt
37. Ccris 6896
38. Einecs 205-447-7
39. Unii-r5l488ry0q
40. Ferrofumarate
41. Heferol
42. Orgasal
43. Ferrous Fumarate [usp:jan]
44. Feostat (tn)
45. Ferrum (tn)
46. Iron (as Fumarate)
47. Meterfer
48. Iron (as Ferrous Fumarate)
49. Schembl24284
50. Schembl24286
51. Ferrous Fumarate (jan/usp)
52. Ferrous Fumarate [ii]
53. Ferrous Fumarate [mi]
54. Ferrous Fumarate [fcc]
55. Ferrous Fumarate [jan]
56. Ferrous Fumarate [inci]
57. Dtxsid7047148
58. Ferrous Fumarate [vandf]
59. Chebi:31607
60. Amy8976
61. Ferrous Fumarate [mart.]
62. Ferrous Fumarate [who-dd]
63. Ferrous Fumarate [who-ip]
64. Hy-b1651
65. Einecs 231-731-5
66. Mfcd00058315
67. Akos015918237
68. Ferrous Fumarate [orange Book]
69. Db14491
70. Ferrosi Fumaras [who-ip Latin]
71. Ferrous Fumarate [ep Monograph]
72. Ferrous Fumarate [usp Monograph]
73. Iron (as Ferrous Fumarate) [vandf]
74. 2-butenedioic Acid (2e)-, Iron(2+) Salt
75. Cs-0013603
76. Norquest Fe Component Ferrous Fumarate
77. D01194
78. Ferrous Fumarate Component Of Norquest Fe
79. Lo Minastrin Fe Component Ferrous Fumarate
80. Minastrin 24 Fe Component Ferrous Fumarate
81. Q416370
82. 2-butenedioic Acid (2e)-, Iron(2+) Salt (1:?)
83. J-007445
84. J-521364
85. 7705-12-6
Molecular Weight | 169.90 g/mol |
---|---|
Molecular Formula | C4H2FeO4 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 0 |
Exact Mass | 169.930244 g/mol |
Monoisotopic Mass | 169.930244 g/mol |
Topological Polar Surface Area | 80.3 Ų |
Heavy Atom Count | 9 |
Formal Charge | 0 |
Complexity | 108 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Ferrous fumarate |
Active Ingredient | Ferrous fumarate |
Dosage Form | Tablet |
Route | oral |
Strength | 75mg |
Market Status | Tentative Approval |
Company | Barr Labs |
2 of 2 | |
---|---|
Drug Name | Ferrous fumarate |
Active Ingredient | Ferrous fumarate |
Dosage Form | Tablet |
Route | oral |
Strength | 75mg |
Market Status | Tentative Approval |
Company | Barr Labs |
Used in preventing and treating iron-deficiency anemia.
The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.
Trace Elements
A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)
B - Blood and blood forming organs
B03 - Antianemic preparations
B03A - Iron preparations
B03AA - Iron bivalent, oral preparations
B03AA02 - Ferrous fumarate
B - Blood and blood forming organs
B03 - Antianemic preparations
B03A - Iron preparations
B03AD - Iron in combination with folic acid
B03AD02 - Ferrous fumarate
Absorption
The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.
Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17321
Submission : 2004-04-16
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33135
Submission : 2018-11-23
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 211
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24184
Submission : 2010-09-13
Status : Inactive
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29276
Submission : 2015-03-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34498
Submission : 2021-02-12
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?